The Future Looks Brighter After 25 Years of Retinal Gene Therapy.

The first report of in vivo gene delivery to the retina dates back to 1987 when a retroviral vector was injected intraocularly in newborn mice. Later came the observation that retinal cells could be successfully transduced using adenoviral and then adeno-associated and lentiviral vectors. By 2000, it had become clear that the eye, compared to other organs and tissues, provides a number of advantages for in vivo gene therapy with regard to safety, efficacy, and route to clinical application. This has prompted the development of many successful proof-of-concept studies in animal models. The demonstration that sight could be restored in a large-animal model with a congenital form of blindness was a major landmark that opened the door to the first-in-human trials for recessively inherited blinding conditions. With these first human studies demonstrating safety as well as some efficacy, retinal gene therapy has now come of age. Rapid clinical development has highlighted various new challenges, including the treatment of patients with advanced photoreceptor degeneration or dominantly inherited retinal dystrophies and those with defects in large genes. Yet, given the progress over the last 25 years, a bright future is expected for retinal gene therapy.

[1]  Kathleen A. Marshall,et al.  Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial , 2017, The Lancet.

[2]  P. Campochiaro,et al.  Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial , 2017, The Lancet.

[3]  L. Montoliu,et al.  A history of genome editing in mammals , 2017, Mammalian Genome.

[4]  T. Aleman,et al.  Evaluation of Dose and Safety of AAV7m8 and AAV8BP2 in the Non-Human Primate Retina. , 2017, Human gene therapy.

[5]  I. Constable,et al.  Phase 2a Randomized Clinical Trial: Safety and Post Hoc Analysis of Subretinal rAAV.sFLT-1 for Wet Age-related Macular Degeneration , 2016, EBioMedicine.

[6]  F. Cocchiarella,et al.  In vivo Editing of the Human Mutant Rhodopsin Gene by Electroporation of Plasmid-based CRISPR/Cas9 in the Mouse Retina , 2016, Molecular therapy. Nucleic acids.

[7]  J. Duncan,et al.  Long-term Follow-up of Patients With Retinitis Pigmentosa Receiving Intraocular Ciliary Neurotrophic Factor Implants. , 2016, American journal of ophthalmology.

[8]  Olivier Marre,et al.  Red‐shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina , 2016, EMBO molecular medicine.

[9]  M. Michaelides,et al.  Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 , 2016, Gene Therapy.

[10]  Mario Renda,et al.  Rhodopsin targeted transcriptional silencing by DNA-binding , 2016, eLife.

[11]  W. Feuer,et al.  Gene Therapy for Leber Hereditary Optic Neuropathy: Initial Results. , 2016, Ophthalmology.

[12]  Jing Yu,et al.  Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis , 2015, Drug design, development and therapy.

[13]  Annette E. Allen,et al.  Restoration of Vision with Ectopic Expression of Human Rod Opsin , 2015, Current Biology.

[14]  Ru Xiao,et al.  In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector. , 2015, Cell reports.

[15]  S. E. Barker,et al.  Long-term effect of gene therapy on Leber's congenital amaurosis. , 2015, The New England journal of medicine.

[16]  K. Palczewski,et al.  P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. , 2014, Human molecular genetics.

[17]  F. Cremers,et al.  Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial , 2014, The Lancet.

[18]  R. Polishchuk,et al.  Effective delivery of large genes to the retina by dual AAV vectors , 2013, EMBO molecular medicine.

[19]  W. Hauswirth,et al.  Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach , 2013, Gene Therapy.

[20]  Deniz Dalkara,et al.  In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous , 2013, Science Translational Medicine.

[21]  J. Bennett,et al.  AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina , 2013, PloS one.

[22]  Alexander Sumaroka,et al.  Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement , 2013, Proceedings of the National Academy of Sciences.

[23]  J. Loader,et al.  Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat(®), for age-related macular degeneration. , 2012, Human gene therapy.

[24]  R. Ali,et al.  Gene supplementation therapy for recessive forms of inherited retinal dystrophies , 2011, Gene Therapy.

[25]  W. Hauswirth,et al.  XIAP therapy increases survival of transplanted rod precursors in a degenerating host retina. , 2011, Investigative ophthalmology & visual science.

[26]  W. Hauswirth,et al.  Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[27]  U. Wolfrum,et al.  Suppression and Replacement Gene Therapy for Autosomal Dominant Disease in a Murine Model of Dominant Retinitis Pigmentosa , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[28]  Karl Deisseroth,et al.  Genetic Reactivation of Cone Photoreceptors Restores Visual Responses in Retinitis Pigmentosa , 2010, Science.

[29]  John G. Flannery,et al.  A Novel Adeno-Associated Viral Variant for Efficient and Selective Intravitreal Transduction of Rat Müller Cells , 2009, PloS one.

[30]  W. Hauswirth,et al.  Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. , 2008, Human gene therapy.

[31]  W. Hauswirth,et al.  Phase I Trial of Leber Congenital Amaurosis due to RPE65 Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results , 2008 .

[32]  Kathleen A. Marshall,et al.  Safety and efficacy of gene transfer for Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[33]  Nick Tyler,et al.  Effect of gene therapy on visual function in Leber's congenital amaurosis. , 2008, The New England journal of medicine.

[34]  C. Mussolino,et al.  Novel Adeno-Associated Virus Serotypes Efficiently Transduce Murine Photoreceptors , 2007, Journal of Virology.

[35]  Toru Ishizuka,et al.  Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. , 2007, Investigative ophthalmology & visual science.

[36]  R. MacLaren,et al.  In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[37]  A. Dizhoor,et al.  Ectopic Expression of a Microbial-Type Rhodopsin Restores Visual Responses in Mice with Photoreceptor Degeneration , 2006, Neuron.

[38]  W. Mieler,et al.  Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Bennett,et al.  Adeno-associated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity , 2004, Current eye research.

[40]  A. Auricchio.  Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye , 2003, Vision Research.

[41]  R. Ali,et al.  Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration , 2003, Gene Therapy.

[42]  W. Hauswirth,et al.  Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[43]  R. Ali,et al.  Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. , 2001, Human molecular genetics.

[44]  Jean Bennett,et al.  Gene therapy restores vision in a canine model of childhood blindness , 2001, Nature Genetics.

[45]  F. Liang,et al.  AAV-mediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  W. Hauswirth,et al.  Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[47]  D. Hunt,et al.  Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy , 2000, Nature Genetics.

[48]  F. Gage,et al.  Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[49]  W. Hauswirth,et al.  Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  T. Dryja,et al.  Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Hunt,et al.  Gene transfer into the mouse retina mediated by an adeno-associated viral vector. , 1996, Human molecular genetics.

[52]  G. Dickson,et al.  Adenovirus‐mediated gene transfer to murine retinal cells in vitro and in vivo , 1994, FEBS letters.

[53]  B. Davidson,et al.  In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. , 1994, Investigative ophthalmology & visual science.

[54]  P. Campochiaro,et al.  Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study. , 2017, Human gene therapy.

[55]  Andreas Möglich,et al.  Channelrhodopsin engineering and exploration of new optogenetic tools , 2011, Nature Methods.

[56]  C. Cepko,et al.  Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. , 1987, Proceedings of the National Academy of Sciences of the United States of America.